The Covid vaccine candidate tested by the University of Oxford has proven successful in animal tests showing encouraging signs to take it forward with human trials. UK’s biggest vaccine project to fight coronavirus infection, ChAdOx1 nCoV-19 trials have shown promising results in monkeys with infected with the virus.
According to experts involved in the trial, which is yet to be peer-reviewed, the vaccine had shown signs of priming the rhesus macaque monkey’s immune system to fend off the deadly virus and at the same showed no indication of adverse effects.
“Even a single vaccination dose, which induces a humoral and cellular immune response in the monkeys, was also found effective in preventing damage to the lungs– the organ that gets severely affected by the virus,” the clinical researchers confirmed to media.
“We observed a significantly reduced viral load in the bronchoalveolar lavage fluid and respiratory tract tissue of vaccinated animals challenged with SARS-CoV-2 virus as compared with controlled animals,” they added.
The researchers said that after being exposed to high levels of novel coronavirus none of the six monkeys, which were vaccinated, showed viral pneumonia. These results supported the vaccine to be taken to the human trials and the results from these trails are eagerly awaited, the researcher said.
Meanwhile, British drug giant Astra Zeneca has signed a deal with the University of Oxford to produce and commercialise the vaccine and, if proved successful in human studies, the company will be able to develop and produce at least 100 million doses of the vaccine by the end of the year.